Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 1999

Primary Completion Date

September 30, 2002

Conditions
Breast Cancer
Interventions
BIOLOGICAL

trastuzumab

"Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.~The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation-functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and causes breast cells to reproduce uncontrollably."

DRUG

vinorelbine ditartrate

Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.

Trial Locations (1)

03756-0002

Norris Cotton Cancer Center, Lebanon

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dartmouth-Hitchcock Medical Center

OTHER